Bora Adds Small-Scale Isolator Line to Baltimore Facility
The company has added the further sterile fill/finish capacity to the site in response to continued growth in demand for its drug product services.
International CDMO, Bora Pharmaceuticals, has announced that it is further expanding its sterile fill/finish capacity in Baltimore, Md., to meet growing industry demand (1). To expand capacity, the company is adding an automated vial, syringe, and cartridge line, AST GENiSYS C, which will work under full isolator conditions.
“Bora is more frequently seeing demand for drug product fill and finish of potent drug candidates and approved treatments, as well as for rare and orphan diseases,” commented J.D. Mowery, President of Bora’s CDMO Division, in a company press release (1). “The addition of a precision small-scale isolator line adds to our overall capacity, and working in concert with our existing large-scale lines, increases our flexibility and scalability. I look forward to adding to our capabilities in the U.S. so that we remain ready to meet rising demand from clients, both domestic and international.”
The company’s 87,000 sq. ft. facility, which was acquired from Emergent in 2024 (2), delivers drug manufacturing services for sterile injectables. Additionally, the facility provides commercial non-viral aseptic fill/finish services of vials and pre-filled syringes on four fill lines, as well as lyophilization, formulation development, and support services for customers.
“Following on the heels of our recent acquisition of Upsher-Smith Laboratories, the Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO,” explained Bobby Sheng, Chairman and CEO of Bora Group, in a press release about the facility acquisition (2). “We look forward to further enhancing the capabilities at the site and welcoming the hugely talented team in Camden to our global family.”
According to market research, the sterile injectables market is expected to grow at a compound annual rate of 7.9% between 2025 and 2032, driven by factors including the rising rates of chronic diseases, an aging global population, increasing demand for self-administered injectable drugs. North America is the dominant region in the field, taking up over 40% of the market share (3).
Additionally, as a result of the general sterile injectables market buoyancy, other research has forecast significant growth for CDMOs in the space. A report by Grand View Research has specified that the sterile injectables CDMO market will grow at a compound annual rate of 9.61% over the next five years, with high demand for sterile products propelling growth (4).
References
Bora Pharmaceuticals. Bora Adds Automated Fill/Finish Line in Baltimore. Press Release, May 29, 2025.
Bora Pharmaceuticals. Bora Completes Acquisition of U.S. Sterile Fill/Finish Facility from Emergent. Press Release, Aug. 20, 2024.
Coherent Market Insights. Sterile Injectables Market Analysis and Forecast: 2025–2032. Market Research Report, February 2025.
Grand View Research. Sterile Injectables CDMO Market Size, Share and Trends Analysis Report by Molecule Type (Small Molecule, Large Molecule), by Product, by Service, by Therapeutic Area, by Route of Administration, by End-use, by Region, and Segment Forecasts, 2025–2030. Market Research Report, Jan. 20, 2025.